Xerostomia

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
1
ElectrostimulationPhase 41 trial
Active Trials
NCT00509808Completed200Est. Apr 2010
Camurus
CamurusSweden - Lund
1 program
1
XER2020Phase 41 trial
Active Trials
NCT01316393CompletedEst. Jun 2011
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Remineralizing Extreme Dry Mouth Spray with XylitolN/A1 trial
Active Trials
NCT04608773Completed129Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CamurusXER2020
Jerusalem PharmaceuticalsElectrostimulation
Johnson & JohnsonRemineralizing Extreme Dry Mouth Spray with Xylitol

Clinical Trials (3)

Total enrollment: 329 patients across 3 trials

Effects of Mucoprotective Product on Xerostomia

Start: Feb 2011Est. completion: Jun 2011
Phase 4Completed

Evaluation of an Electro-stimulator for the Treatment of Xerostomia

Start: Jan 2007Est. completion: Apr 2010200 patients
Phase 4Completed
NCT04608773Johnson & JohnsonRemineralizing Extreme Dry Mouth Spray with Xylitol

Blinded Dry Mouth Spray Crossover Study

Start: Jan 2021Est. completion: Jun 2023129 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space